Menactra, now available, may demand parent payments

Why This Topic Matters

New vaccine launches can affect both clinical immunization planning and practice revenue. Understanding the article helps readers anticipate payer behavior, vaccine demand, and the general coding and billing context around newly available vaccines.

Article Sections

1. AAP guidance and vaccine availability

   This section covers the release of a newer meningococcal vaccine, the role of the AAP policy statement, and the general population groups discussed in relation to vaccination. It also places the topic in the context of FDA approval and product availability.

2. Reimbursement and practice payment concerns

   This section addresses payer coverage concerns, cost pressures on pediatric practices, and the broader reimbursement challenges that can follow introduction of a new vaccine. It also mentions how other upcoming vaccines fit into the same payment environment.

3. Other meningococcal vaccine context

   This section compares the newer vaccine with an older meningococcal product and discusses general availability, age-related considerations, and manufacturer-related context. It provides background on how different products in the same category may be viewed in practice.

4. Administration and scheduling reminders

   This brief section notes general administration coding for vaccine delivery and reminds readers about use when the vaccine is given alone or alongside another immunization. It also references common seasonal demand for vaccination in adolescents and college-bound patients.